BioJapan 2025

Richmond Pharmacology is excited to confirm our attendance at BioJapan 2025, Asia’s leading biotechnology partnering event, taking place in Yokohama from 8^th–10^th October.

Representing Richmond at BioJapan:

·        Dr Jörg Täubel, Chief Executive Officer

·        Dr Ulrike Lorch, Chief Medical Director

·        Stephen Wilkinson, Business Development Manager

·        Nobuo Ittetsu, Head of Japanese Volunteer Recruitment

·        Minoru Takada, Japanese Business Development Executive

We look forward to connecting with global partners, sharing insights and exploring opportunities in:

•Early-phase trials for biologics and advanced therapies

•UK–Japan collaboration in gene editing and RNA medicines

•Regulatory strategy across Asia and Europe

•Bridging studies and multi-regional trial design

•Patient-centric and adaptive trial models

If you’re attending BioJapan 2025 and are looking to collaborate in translational research or clinical development, get in touch to arrange a meeting: info@richmondpharmacology.com

Learn more: BioJapan/ 再生医療JAPAN/ healthTECH JAPAN